scholarly journals Alterations in the motor neuron-renshaw cell circuit in the Sod1 G93A mouse model

2013 ◽  
Vol 521 (7) ◽  
pp. Spc1-Spc1
Author(s):  
Hanna Wootz ◽  
Eileen FitzSimons-Kantamneni ◽  
Martin Larhammar ◽  
Travis M. Rotterman ◽  
Anders Enjin ◽  
...  

2013 ◽  
Vol 521 (7) ◽  
pp. 1449-1469 ◽  
Author(s):  
Hanna Wootz ◽  
Eileen FitzSimons-Kantamneni ◽  
Martin Larhammar ◽  
Travis M. Rotterman ◽  
Anders Enjin ◽  
...  




2021 ◽  
Vol 22 (19) ◽  
pp. 10649
Author(s):  
Savina Apolloni ◽  
Paola Fabbrizio ◽  
Susanna Amadio ◽  
Giulia Napoli ◽  
Mattia Freschi ◽  
...  

Amyotrophic lateral sclerosis (ALS) is a disease with a resilient neuroinflammatory component caused by activated microglia and infiltrated immune cells. How to successfully balance neuroprotective versus neurotoxic actions through the use of anti-inflammatory agents is still under debate. There has been a boost of awareness regarding the role of extracellular ATP and purinergic receptors in modulating the physiological and pathological mechanisms in the nervous system. Particularly in ALS, it is known that the purinergic ionotropic P2X7 receptor plays a dual role in disease progression by acting at different cellular and molecular levels. In this context, we previously demonstrated that the P2X7 receptor antagonist, brilliant blue G, reduces neuroinflammation and ameliorates some of the pathological features of ALS in the SOD1-G93A mouse model. Here, we test the novel, noncommercially available, and centrally permeant Axxam proprietary P2X7 antagonist, AXX71, in SOD1-G93A mice, by assessing some behavioral and molecular parameters, among which are disease progression, survival, gliosis, and motor neuron wealth. We demonstrate that AXX71 affects the early symptomatic phase of the disease by reducing microglia-related proinflammatory markers and autophagy without affecting the anti-inflammatory markers or motor neuron survival. Our results suggest that P2X7 modulation can be further investigated as a therapeutic strategy in preclinical studies, and exploited in ALS clinical trials.



2010 ◽  
Vol 113 (2) ◽  
pp. 489-501 ◽  
Author(s):  
Marco Milanese ◽  
Simona Zappettini ◽  
Emanuela Jacchetti ◽  
Tiziana Bonifacino ◽  
Chiara Cervetto ◽  
...  


2019 ◽  
Vol 10 (6) ◽  
pp. 1159 ◽  
Author(s):  
Xiaojie Zhang ◽  
Sheng Chen ◽  
Kaili Lu ◽  
Feng Wang ◽  
Jiangshan Deng ◽  
...  




2009 ◽  
Vol 34 (3) ◽  
pp. 511-517 ◽  
Author(s):  
Bradley J. Turner ◽  
Nicholas J. Parkinson ◽  
Kay E. Davies ◽  
Kevin Talbot


Sign in / Sign up

Export Citation Format

Share Document